Josh Jennings, an analyst from TD Cowen, maintained the Buy rating on Humacyte (HUMA – Research Report). The associated price target is $5.00.
Josh Jennings has given his Buy rating for Humacyte’s stock due to a combination of factors. One of the primary reasons is the impressive safety and efficacy that Humacyte’s HAV technology has shown in both clinical trial and real-world use settings. This technology was spotlighted in several presentations at VEITH which further emphasised its potential and we believe this solid data will bolster a positive review of the company’s forthcoming BLA submission for an indication in vascular trauma.
Additionally, the Phase 2/3 V005 clinical trial conducted by Humacyte provided compelling data that supports the Buy rating. Specifically, the results from this trial demonstrated a high secondary patency for the HAV in comparison to synthetic grafts. Furthermore, the HAV showed lower rates of amputation and infection compared to synthetic grafts. The reasons reported by clinicians for choosing the HAV over saphenous vein, including the need to avoid time required to harvest saphenous vein and the quality of the patient’s vein, indicate the HAV’s strong value proposition. We believe these factors will contribute to a positive review of Humacyte’s vascular trauma BLA submission, which is expected to be filed in the 4th quarter of 2023.
In another report released on November 10, Oppenheimer also assigned a Buy rating to the stock with a $5.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HUMA in relation to earlier this year.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Humacyte (HUMA) Company Description:
Alpha Healthcare Acquisition Corp is a blank check company.
Read More on HUMA:
- Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma
- Humacyte reports Q3 EPS (25c), consensus (25c)
- Humacyte Third Quarter 2023 Financial Results and Business Update
- Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model
- Humacyte publishes preclinical study on HAV to treat Tetralogy of Fallot
